Cell signaling and cancer treatment

Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial.

ESMO open·2026

HR-SC-an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparib.

ESMO open·2025

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.

British journal of cancer·2023

Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial.

ESMO open·2022

COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC).

ESMO open·2021

Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein.

Biochemical pharmacology·2017

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Atezolizumab with or without tiragolumab in unresectable esophageal squamous cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Eight-year outcomes of testosterone suppression plus enzalutamide or a non-steroidal anti-androgen for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Elucidating PI3K/AKT/PTEN Pathway Alterations at Single-Cell Level in CTCs From HR+/HER2- Metastatic Breast Cancer.

Cancer science·2026

Nanomessenger-Mediated Signal Crosstalk Encodes Multithreading Death Program Against Tumor Metastasis.

Small (Weinheim an der Bergstrasse, Germany)·2026

Inhibition of chondroitin sulfate proteoglycans enhances cell migration following enteric neural stem cell transplantation.

Development (Cambridge, England)·2026

The UVA-induced single-base mutational signature of CX-5461 in human cells.

Nucleic acids research·2026

Effects of Ozone Therapy on the Bladder of Rats with Streptozocin-Induced Diabetes.

Drug design, development and therapy·2026

Clinical Evaluation of Anaplastic Lymphoma Kinase (ALK) Inhibitors for the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer Based on the 2nd Edition of China's Drug Evaluation and Selection Guideline.

Drug design, development and therapy·2026

Related Experiment Videos

Cell signaling and cancer treatment

Related Concept Videos

Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial.

HR-SC-an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparib.

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.

Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial.

COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC).

Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein.

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.

Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study.

Atezolizumab with or without tiragolumab in unresectable esophageal squamous cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study.

Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).

Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer.

Eight-year outcomes of testosterone suppression plus enzalutamide or a non-steroidal anti-androgen for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).

Elucidating PI3K/AKT/PTEN Pathway Alterations at Single-Cell Level in CTCs From HR+/HER2- Metastatic Breast Cancer.

Nanomessenger-Mediated Signal Crosstalk Encodes Multithreading Death Program Against Tumor Metastasis.

Inhibition of chondroitin sulfate proteoglycans enhances cell migration following enteric neural stem cell transplantation.

The UVA-induced single-base mutational signature of CX-5461 in human cells.

Effects of Ozone Therapy on the Bladder of Rats with Streptozocin-Induced Diabetes.

Clinical Evaluation of Anaplastic Lymphoma Kinase (ALK) Inhibitors for the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer Based on the 2nd Edition of China's Drug Evaluation and Selection Guideline.

Related Experiment Videos

Cell signaling and cancer treatment

Related Concept Videos

Related Articles